Akthelia Pharmaceuticals will present its partnering and capital raising objectives at the LSX World Congress in London, April 29-30, 2024 in London
REYKJAVIK, Iceland -- 5 Apr, 2024 -- Akthelia Pharmaceuticals, a leader in immunotherapeutic research and development, is excited to announce its participation in the LSX World Congress, set to take place from April 29-30, 2024, at the Business Design Centre in London, UK.
The 10th LSX World Congress is a pivotal gathering for those at the forefront of driving strategic knowledge and partnerships in the life sciences industry. Akthelia Pharmaceuticals looks forward to engaging with other innovators, sharing insights, and exploring new avenues to accelerate the delivery of its groundbreaking therapies to patients worldwide.
"Akthelia Pharmaceuticals is at a pivotal juncture, with a strongly validated and developable lead asset, ready to enter IND-enabling studies for our groundbreaking immunomodulatory strategies"
With the European Commission's Seal of Excellence as a testament to its innovative approach, Akthelia is now actively seeking strategic partnerships and funding opportunities to propel its lead programs, including AKT-011 for febrile neutropenia / neutropenic sepsis and AKT-021 for wound healing, towards clinical success. The LSX World Congress serves as an ideal platform for Akthelia to connect with potential investors and partners, facilitating discussions on the next phases of development and commercialization.
"Akthelia Pharmaceuticals is at a pivotal juncture, with a strongly validated and developable lead asset, ready to enter IND-enabling studies for our groundbreaking immunomodulatory strategies," said Egill Masson, CEO of Akthelia Pharmaceuticals. "We are thrilled to be part of the LSX World Congress, an event that mirrors our commitment to innovation and collaboration in the life sciences. This is a unique opportunity to showcase our pioneering work in immunotherapeutics and to forge meaningful partnerships that can help address some of the most pressing health challenges of our time and we look forward to securing the partnerships and funds necessary to bring our therapies from the lab to the patients who need them.""
Akthelia Pharmaceuticals invites attendees to join them at this dynamic conference to learn more about their cutting-edge approach to improving oncology outcomes and its revolutionary approach to combat antibiotic microbial resistance (AMR) globally.
To arrange a meeting, please contact CEO Egill Masson, egill.masson@aktheliapharma.com.
ABOUT AKTHELIA PHARMACEUTICALS
Akthelia Pharmaceuticals is a late preclinical-stage biopharmaceutical company, focusing on a novel immunotherapeutic strategy that upregulates the innate immunity of epithelial surfaces.
Akthelia is pioneering solutions to improve cancer care outcomes by reducing the risk of chemotherapy-induced bloodstream infections. Akthelia's platform also addresses the urgent global threat of antibiotic bacterial resistance (AMR).
CONTACTS
Egill Masson CEO egill.masson@aktheliapharma.com
Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland